Vical Halts Development of HSV-2 Vaccine after Phase II Failure

Vical acknowledged today that it has halted development of its bivalent vaccine candidate for herpes simplex virus type 2 (HSV-2) after it failed a Phase II trial—the company’s second clinical setback this year involving a lead product.The HSV-2 vaccine missed its primary endpoint in the Phase II study ( NCT02837575 ) of annualized lesion recurrence rate calculated based on those genital recurrences that were both clinically and virologically confirmed during a minimum of nine months